Drug intelligence / Profile preview

EB-105 (Elastin Biosciences)

Development stage: Preclinical
Lead developer: Elastin Biosciences
Modality: Small Molecules

Overview

EB-105 is a preclinical-stage small molecule drug candidate being developed by Elastin Biosciences. It is designed to restore tissue structural integrity by boosting the production of elastin and strengthening the elastin-based extracellular matrix. The drug is part of a series of candidates (EB-105 to EB-108) targeting diseases characterized by the loss of or defects in elastin, a critical protein for tissue elasticity. EB-105 is currently under investigation for applications in both cardiovascular diseases and dermatology.

Targets

ELN (Elastin)

Beyond the preview

Go deeper on EB-105 (Elastin Biosciences).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB-105 (Elastin Biosciences).

Explore the full profile